DexCom, Inc. (NASDAQ:DXCM) Receives $104.59 Average Target Price from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have been given a consensus rating of “Moderate Buy” by the eighteen analysts that are covering the stock, Marketbeat reports. Six equities research analysts have rated the stock with a hold recommendation, eleven have given a buy recommendation and one has given a strong buy recommendation to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $104.59.

Several equities analysts have weighed in on the company. Royal Bank of Canada dropped their target price on DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. UBS Group cut their target price on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Stifel Nicolaus increased their target price on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Robert W. Baird boosted their price target on shares of DexCom from $80.00 to $82.00 and gave the stock a “neutral” rating in a research note on Monday, August 5th. Finally, Raymond James cut their price objective on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research report on Friday, October 25th.

Insider Activity at DexCom

In other news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at approximately $18,318,872.25. This represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the firm’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at approximately $5,217,436.65. This trade represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 0.30% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of the stock. Migdal Insurance & Financial Holdings Ltd. acquired a new stake in DexCom in the second quarter valued at about $25,000. Sachetta LLC lifted its holdings in shares of DexCom by 255.2% in the 2nd quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the period. Crewe Advisors LLC purchased a new stake in shares of DexCom in the first quarter valued at approximately $29,000. Riverview Trust Co grew its holdings in DexCom by 100.4% during the third quarter. Riverview Trust Co now owns 463 shares of the medical device company’s stock worth $31,000 after acquiring an additional 232 shares during the period. Finally, DT Investment Partners LLC raised its position in DexCom by 492.2% in the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after acquiring an additional 315 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

DexCom Trading Down 1.0 %

DXCM opened at $74.48 on Tuesday. DexCom has a 52 week low of $62.34 and a 52 week high of $142.00. The company has a quick ratio of 2.12, a current ratio of 2.46 and a debt-to-equity ratio of 1.23. The business has a fifty day simple moving average of $70.43 and a 200-day simple moving average of $90.34. The firm has a market cap of $29.09 billion, a P/E ratio of 45.05, a P/E/G ratio of 2.30 and a beta of 1.17.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.